Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method
Authors:
- S. LeuchtSLS. Leucht
- M. SamaraMSM. Samara
- S. HeresSHS. Heres
- M. X. PatelMPM. X. Patel
- S. W. WoodsSWS. W. Woods
- J. M. DavisJDJ. M. Davis
- 3 February 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 40 (2) , 314-326
Abstract
Clinicians need to know the right antipsychotic dose for optimized treatment, and the concept of dose equivalence is important for many clinical and scientific purposes. We refined a method presented in 2003, which was based on the minimum effective doses found in fixed-dose studies. We operationalized the selection process, updated the original findings, and expanded them by systematically searching more recent literature and by including 13 second-generation antipsychotics. To qualify for the minimum effective dose, a dose had to be significantly more efficacious than placebo in the primary outcome of at least one randomized, double-blind, fixed-dose trial. In a sensitivity analysis, 2 positive trials were required. The minimum effective doses identified were subsequently used to derive olanzapine, risperidone, haloperidol, and chlorpromazine equivalents. We reviewed 73 included studies. The minimum effective daily doses/olanzapine equivalents based on our primary approach were: aripiprazole 10 mg/1.33, asenapine 10 mg/1.33, clozapine 300 mg/40, haloperidol 4 mg/0.53, iloperidone 8 mg/1.07, lurasidone 40 mg/5.33, olanzapine 7.5 mg/1, paliperidone 3 mg/0.4, quetiapine 150 mg/20, risperidone 2 mg/0.27, sertindole 12 mg/1.60, and ziprasidone 40 mg/5.33. For amisulpride and zotepine, reliable estimates could not be derived. This method for determining antipsychotic dose equivalence entails an operationalized and evidence-based approach that can be applied to the various antipsychotic drugs. As a limitation, the results are not applicable to specific populations such as first-episode or refractory patients. We recommend that alternative methods also be updated in order to minimize further differences between the methods and risk of subsequent bias.Keywords
This publication has 88 references indexed in Scilit:
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D2 receptor antagonist in the treatment of acute exacerbation of schizophreniaEuropean Neuropsychopharmacology, 2012
- Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled studyPsychopharmacology, 2012
- Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?International Journal of Neuropsychopharmacology, 2012
- A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV SchizophreniaJournal of Clinical Psychopharmacology, 2011
- Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different DrugsBiological Psychiatry, 2010
- What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?Schizophrenia Bulletin, 2008
- Efficacy and Tolerability of Asenapine in Acute SchizophreniaThe Journal of Clinical Psychiatry, 2007
- Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trialNature Medicine, 2007
- ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophreniaClinical Therapeutics, 1995